Clinical Trial Update: Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

A completed Phase 1 study of AR-12 in adults with advanced or recurrent solid tumors or lymphoma to assess safety and preliminary activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide)

Snippet

Sponsor: Arno Therapeutics | Conditions: Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED